Primary leukemia samples showed heterogeneous sensitivity to CAL-101: viability EC50 values below 1 μM occurred in 5/22 B-ALL and 11/42 CLL samples, versus 1/31 AML and 0/39 MPN samples. Five normal PBMC samples showed no sensitivity in this screen. [1]
At 5 μM, CAL-101 reduced CXCL12- and CXCL13-directed migration of primary CLL cells in a Transwell assay (10 patients). This migration endpoint complements the viability evidence. [2]
Recombinant PI3K isoform inhibition
Biochemical assay · Recombinant class I PI3Ks [1]
CAL-101 inhibited p110δ more potently than the other class I isoforms.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5.0–10^4 nM
- Method
- In vitro enzyme inhibition profiling
- Vehicle
- DMSO stock, 10 mM
- Reported limits
- Reaction duration and replicate counts are not given in the read main caption; linked SI not acquired.
Methods and source locations
Compound reported in the paper: CAL-101 (idelalisib); Compound label in the paper: CAL-101
Named-compound evidence; tested material does not establish purity, potency or performance of an Adooq lot.
Figure 1A-B and caption; Methods: In vitro kinase profiling; selectivity Results
Recombinant class I PI3K inhibition: 10-point enzyme inhibitory activity profiling; ATP at each enzyme’s Km. — Figure 1B (viewed table); caption
Heterogeneous sensitivity of primary leukemia samples
Cell-based study · Primary B-ALL (n=22), CLL (n=42), AML (n=31), MPN (n=39); normal PBMC samples (n=5) [1]
Only subsets of B-ALL and CLL samples met the authors’ sensitivity threshold; most samples did not.
Literature-Reported Treatment Conditions
- Treatment concentration
- Maximum tested: 10 μM
- Method
- Ex vivo viability concentration-response screen
- Reported limits
- Exposure duration and final vehicle fraction are not specified in the read main text; SI not acquired. No duration inferred from neighboring apoptosis experiments.
Methods and source locations
Compound reported in the paper: CAL-101 (idelalisib); Compound label in the paper: CAL-101
Named-compound evidence; tested material does not establish purity, potency or performance of an Adooq lot.
Figure 2A and caption; primary-cell sensitivity Results; main Methods
Samples with viability EC50 <1 μM: Tetrazolium-based viability assay; sensitivity relative to untreated cells; maximum tested concentration 10 μM. — Sensitivity of primary cells Results; Figure 2A caption
Normal peripheral blood mononuclear cell sensitivity: Same primary-cell screen; no numerical normal-cell EC50 assigned. — Primary-cell sensitivity Results; Figure 2A
Reduced chemokine-directed migration of primary CLL cells
Cell-based study · Primary CLL cells from 10 patients; Transwell migration toward CXCL12 or CXCL13 [2]
CAL-101 reduced migration toward both chemokines relative to no-drug controls.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5 μM
- Exposure duration
- 1-hour pretreatment; 3-hour migration assay
- Method
- Methods describe anti-IgM (10 μg/mL) during pretreatment, with or without CAL-101; chemokine-free control also included.
- Vehicle
- DMSO stock, 10 mM; final fraction not specified
- Reported limits
- Figure 1A caption omits anti-IgM, which is explicitly included in the Chemotaxis assay Methods. Final vehicle-matching details not stated there.
Methods and source locations
Compound reported in the paper: CAL-101 (idelalisib); Compound label in the paper: CAL-101
Named-compound evidence; tested material does not establish purity, potency or performance of an Adooq lot.
Methods: Chemotaxis assay and data analysis; first Results subsection; Figure 1A and caption
Cells migrating toward CXCL12: Transwell assay with 200 ng/mL CXCL12; flow-cytometric counting. — First Results subsection; Figure 1A
Cells migrating toward CXCL13: Transwell assay with 1 μg/mL CXCL13; flow-cytometric counting. — First Results subsection; Figure 1A